The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Galectin-1: A Link Between Tumor Hypoxia and Tumor Immune Privilege
Open accessAbstract
Purpose: To identify a 15-KDa novel hypoxia-induced secreted protein in head and neck squamous cell carcinomas (HNSCC) and to determine its role in malignant progression. Methods: We used surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and tandem MS to identify a novel hypoxia-induced secreted protein in FaDu cells. We used immunoblots, real-time polymerase chain reaction (PCR), and enzyme-linked immunoabsorbent assay to confirm the hypoxic induction of this secreted protein as galectin-1 in cell lines and xenografts. We stained tumor tissues from 101 HNSCC patients for galectin-1, CA IX (carbonic anhydrase IX, a hypoxia marker) and CD3 (a T-cell marker). Expression of these markers was correlated to each other and to treatment outcomes. Results: SELDI-TOF studies yielded a hypoxia-induced peak at 15 kDa that proved to be galectin-1 by MS analysis. Immunoblots and PCR studies confirmed increased galectin-1 expression by hypoxia in several cancer cell lines. Plasma levels of galectin-1 were higher in tumor-bearing severe combined immunodeficiency (SCID) mice breathing 10% O 2 compared with mice breathing room air. In HNSCC patients, there was a significant correlation between galectin-1 and CA IX staining (P = .01) and a strong inverse correlation between galectin-1 and CD3 staining (P = .01). Expression of galectin-1 and CD3 were significant predictors for overall survival on multivariate analysis. Conclusion: Galectin-1 is a novel hypoxia-regulated protein and a prognostic marker in HNSCC. This study presents a new mechanism on how hypoxia can affect the malignant progression and therapeutic response of solid tumors by regulating the secretion of proteins that modulate immune privilege.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Galectins as modulators of tumour progression
Liu, F.-T., & Rabinovich, G. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1527 · Cited by 1,439
Apoptosis of T cells mediated by galectin-1
Perillo, N. L., Pace, K. E., Seilhamer, J. J., & Baum, L. G. (1995) · Nature · doi:10.1038/378736a0 · Cited by 1,074
Secretion of the galectin family of mammalian carbohydrate-binding proteins
Hughes, R. (1999) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00177-4 · Cited by 636
XBP1 Is Essential for Survival under Hypoxic Conditions and Is Required for Tumor Growth
Romero-Ramirez, L., Cao, H., Nelson, D., Hammond, E., Lee, A.-H., Yoshida, H., Mori, K., Glimcher, L. H., Denko, N. C., Giaccia, A. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1606 · Cited by 570
Self-citationOxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome
Brizel, D. M., Dodge, R. K., Clough, R. W., & Dewhirst, M. W. (1999) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00102-4 · Cited by 548
Rubinstein, N., Alvarez, M., Zwirner, N. W., Toscano, M. A., Ilarregui, J. M., Bravo, A., Mordoh, J., Fainboim, L., Podhajcer, O. L., & Rabinovich, G. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00024-8 · Cited by 531
Transcriptional Response to Hypoxia in Human Tumors
Lal, A., Peters, H., St. Croix, B., Haroon, Z. A., Dewhirst, M. W., Strausberg, R. L., Kaanders, J. H. A. M., van der Kogel, A. J., & Riggins, G. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.17.1337 · Cited by 320
Swinson, D. E. B., Jones, J. L., Richardson, D., Wykoff, C., Turley, H., Pastorek, J., Taub, N., Harris, A. L., & O’Byrne, K. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.132 · Cited by 287
Self-citationKopitz, J., von Reitzenstein, C., André, S., Kaltner, H., Uhl, J., Ehemann, V., Cantz, M., & Gabius, H.-J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105135200 · Cited by 281
Cited by
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
The hypoxic tumour microenvironment
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,019
Turning 'sweet' on immunity: galectin–glycan interactions in immune tolerance and inflammation
Rabinovich, G. A., & Toscano, M. A. (2009) · Nature Reviews Immunology · doi:10.1038/nri2536 · Cited by 904
Galectin-1: a small protein with major functions
Camby, I., Le Mercier, M., Lefranc, F., & Kiss, R. (2006) · Glycobiology · doi:10.1093/glycob/cwl025 · Cited by 893
Emami Nejad, A., Najafgholian, S., Rostami, A., Sistani, A., Shojaeifar, S., Esparvarinha, M., Nedaeinia, R., Haghjooy Javanmard, S., Taherian, M., Ahmadlou, M., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01719-5 · Cited by 693
Croci, D. O., Cerliani, J. P., Dalotto-Moreno, T., Méndez-Huergo, S. P., Mascanfroni, I. D., Dergan-Dylon, S., Toscano, M. A., Caramelo, J. J., García-Vallejo, J. J., Ouyang, J., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.043 · Cited by 505
The ever-expanding role of HIF in tumour and stromal biology
LaGory, E. L., & Giaccia, A. J. (2016) · Nature Cell Biology · doi:10.1038/ncb3330 · Cited by 430
Self-citationJuszczynski, P., Ouyang, J., Monti, S., Rodig, S. J., Takeyama, K., Abramson, J., Chen, W., Kutok, J. L., Rabinovich, G. A., & Shipp, M. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706017104 · Cited by 327
Balermpas, P., Michel, Y., Wagenblast, J., Seitz, O., Weiss, C., Rödel, F., Rödel, C., & Fokas, E. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.640 · Cited by 309
Galectin expression in cancer diagnosis and prognosis: A systematic review
Thijssen, V. L., Heusschen, R., Caers, J., & Griffioen, A. W. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.003 · Cited by 279
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
Wu, A. A., Drake, V., Huang, H.-S., Chiu, S., & Zheng, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1016700 · Cited by 271
Dalotto-Moreno, T., Croci, D. O., Cerliani, J. P., Martinez-Allo, V. C., Dergan-Dylon, S., Méndez-Huergo, S. P., Stupirski, J. C., Mazal, D., Osinaga, E., Toscano, M. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2418 · Cited by 261
Messaoudi, K., Clavreul, A., & Lagarce, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.011 · Cited by 238
Upreti, M., Jyoti, A., Johnson, S. E., Swindell, E. P., Napier, D., Sethi, P., Chan, R., Feddock, J. M., Weiss, H. L., O’Halloran, T. V., et al. (2106) · Oncotarget · doi:10.18632/oncotarget.9490 · Cited by 21
“These include breast [57], colon [58], lung [59], head & neck [60], ovarian [61] and prostrate [62] carcinomas in addition to gliomas [63], Kaposi’s sarcoma [64], myeloproliferative neoplasia [65] and Hodgkin lymphoma [66].”
Background
Metadata
- Authors
- Le, Q.-T., Shi, G., Cao, H., Nelson, D. W., Wang, Y., Chen, E. Y., Zhao, S., Kong, C., Richardson, D., O'Byrne, K. J., Giaccia, A. J., & Koong, A. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-10
- Volume
- 23
- Issue
- 35
- Pages
- 8932-8941
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1538326806
- Cited by
- 258
- References
- 33
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.